Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $195.92 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $116.49 | 1 | $0 (2023) |
| Genentech USA, Inc. | $39.21 | 3 | $0 (2021) |
| ABBVIE INC. | $28.96 | 2 | $0 (2022) |
| VBI Vaccines (Delaware) Inc. | $11.26 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $116.49 | 1 | PFIZER INC. ($116.49) |
| 2022 | $29.03 | 2 | ABBVIE INC. ($17.77) |
| 2021 | $50.40 | 4 | Genentech USA, Inc. ($39.21) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $116.49 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 06/08/2022 | VBI Vaccines (Delaware) Inc. | PreHevbrio (Drug) | Food and Beverage | Cash or cash equivalent | $11.26 | General |
| Category: VACCINE | ||||||
| 01/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: NEUROSCIENCE | ||||||
| 02/19/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Virology & Specialty Care | ||||||
| 02/18/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $11.96 | General |
| Category: Virology & Specialty Care | ||||||
| 02/10/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 325 | 458 | $51,317 | $14,761 |
| 2022 | 1 | 11 | 11 | $2,812 | $801.33 |
| 2020 | 2 | 26 | 27 | $21,475 | $1,120 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 54 | 54 | $13,807 | $3,589 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 56 | $12,320 | $3,121 | 25.3% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2023 | 36 | 38 | $2,242 | $1,911 | 85.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $6,626 | $1,649 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 19 | $6,080 | $1,438 | 23.6% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 37 | 74 | $3,445 | $1,200 | 34.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 16 | 17 | $2,040 | $854.76 | 41.9% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 35 | 35 | $1,645 | $567.00 | 34.5% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 15 | 15 | $1,493 | $261.49 | 17.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 13 | $780.00 | $106.08 | 13.6% |
| 81002 | Urinalysis, manual test | Office | 2023 | 16 | 16 | $320.00 | $54.56 | 17.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 12 | 104 | $520.00 | $9.15 | 1.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,812 | $801.33 | 28.5% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 13 | 14 | $13,090 | $803.24 | 6.1% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 13 | 13 | $8,385 | $316.50 | 3.8% |
About Christopher Hill
Christopher Hill is a Family healthcare provider based in Rome, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2017. The National Provider Identifier (NPI) number assigned to this provider is 1225565393.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christopher Hill has received a total of $195.92 in payments from pharmaceutical and medical device companies, with $116.49 received in 2023. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($195.92).
As a Medicare-enrolled provider, Hill has provided services to 362 Medicare beneficiaries, totaling 496 services with total Medicare billing of $16,682. Data is available for 3 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Rome, GA
- Active Since 05/19/2017
- Last Updated 05/19/2017
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1225565393
Products in Payments
- PAXLOVID (Drug) $116.49
- Xofluza (Drug) $39.21
- VRAYLAR (Drug) $28.96
- PreHevbrio (Drug) $11.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Rome
Jamie Thomas, Fnp-C, FNP-C
Family — Payments: $6,460
Ashley Carlile, Np, NP
Family — Payments: $4,868
Mrs. Stephanie Sisson, Np-C, NP-C
Family — Payments: $3,807
Heidi Cannan, Fnp, FNP
Family — Payments: $3,337
Mrs. Chenoa Dickerson, Fnp-C, FNP-C
Family — Payments: $3,241
Farrah Gardner, Np, NP
Family — Payments: $2,806